Fresh analysis indicates that individuals who discontinue popular slimming jabs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who stop conventional lifestyle programs.
Research printed in a leading medical journal demonstrates that while overweight individuals can lose a large proportion of their body weight while undergoing treatment, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation.
"People buying such medications must be informed of the potential of rapid rebound weight gain when the medication ends," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery implies a return to pre-treatment mass in about a year and a half.
Weighing Therapies
The analysis, which looked at 37 of studies involving over 9,000 of participants, contrasted the outcomes of the injectable medications with other pills.
The team point out that individuals who lose weight through dieting generally have a more gradual creep back—approximately 0.1 kg a month—after stopping.
Understanding the Rapid Regain
Doctors believe the mechanism of the drugs is key to understanding the amplified rebound.
GLP-1 drugs mimic a natural hormone called GLP-1, which moderates hunger.
"Artificially providing GLP-1 concentrations far above than the body's typical production could lead to the system to produce less of its endogenous hormone, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this hormone supplement means appetite is uncontrolled, making overeating far more likely."
A Lifelong Condition?
Medical guidelines recommend the injections for people with weight-linked medical conditions, alongside recommended lifestyle changes.
A number of clinicians contend that, given the likelihood of relapse, the treatment should be considered life-long.
This perspective is reinforced by pharmaceutical companies, who state that the findings "underscore the long-term nature of obesity," similar to managing conditions like high blood pressure.
Patient Experiences
Individuals who have discontinued the medication describe a sudden return of hunger.
"It was like a switch that goes on and you become extremely hungry," recalled one woman.
This challenge is exacerbated if patients have not adopted permanent lifestyle or habit changes during treatment.
Significant Adoption
Figures indicate that millions of adults in the UK have tried these injections in the last 12 months, with interest continuing to grow.
- Adoption is more common among women compared to males.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion access the medications through private healthcare rather than public health services.
Ultimately, clinicians stress that while these medications are powerful tools for shedding pounds, they are not a standalone cure and long-term success hinges on combined behavioural support.
